South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

1970: The AVA anthrax vaccine was licensed by BioThrax for use in humans. 1990 t0 1991: An estimated 150,000 troops were given at least one dose of the anthrax vaccine during the Gulf War. 1997 to ...

The company’s only product was the anthrax vaccine, called BioThrax, which it sold chiefly to the U.S. military. In mid-2004, the company reorganized as Emergent BioSolutions.

In May, BioPort Corp., the only manufacturer licensed in the United States to produce an anthrax vaccine, won a $123-million contract to make 5 million doses for the public.

The anthrax vaccine is deemed safe and effective in protecting people from anthrax infection. However, there have been some concerns about its safety in the past, and its use remains controversial.

Here's what to know about the anthrax vaccine, including side effects, ingredients, why it's used, and who it's recommended for.

The voluntary COVID-19 vaccine effort stands in stark contrast to the Pentagon’s mandatory Anthrax Vaccine Immunization Program, which began in 1998. Those who refused often faced harsh penalties.

The government is preparing to buy enough experimental anthrax vaccine for 25 million people, a stockpile that would permit mass inoculations in numerous U.S. cities if terrorists launched a broad ...

The government's $1 billion effort to develop a new anthrax vaccine has run into difficulty, with the company in charge of the project reporting failure in a major human test and falling at least ...

An unknown fraction of service members who were punished for refusing the anthrax vaccine in the late 1990s and early 2000s have sought to have their records corrected, but only a few have had ...

Vaccine That Protects Against Anthrax and Plague Created, Should be Stockpiled by Government. Published Oct 18, 2018 at 9:20 AM EDT Updated Oct 18, 2018 at 1:34 PM EDT.

The anthrax vaccine currently available is safe and effective, but a new one is needed that is easier, faster and less painful to administer, a panel of experts said Wednesday.